- Fitbit has launched a new Device Connect service to give doctors your data
- Wellnex Life has raised $2.8 million to achieve its goal of offering OTC medical cannabis in Australia
- Microba extends agreements with Europe’s largest pathology company through December 2028
Most of Fitbit’s revenue has historically come from the sale of its wearable devices, but its new Device Connect service targets healthcare professionals, doctors and hospitals looking for “accelerated analysis and information” in patients and clients.
Basically, healthcare providers would be able to monitor data and provide care outside of the doctor’s office, such as monitoring a patient’s condition before and after surgery, chronic disease management, or as part of a clinical research study.
Device Connect is already operational at Haga University Hospital in The Hague, the Netherlands, where researchers are using the data to help conduct a study for the early identification and prevention of vascular disease.
And because Google owns Fitbit, the plan is to use Google Cloud technology with pre-built dashboards, including a patient registration and consent app that lets healthcare professionals and businesses access to Fitbit data.
But don’t worry, apparently you’ll still be able to control what data you share and how it’s used.
You trust Google, right?
Who published health news today?
WELLNEX LIFE (ASX:WNX)
The company raised $2.815 million at $0.075 through a stock purchase plan (SPP) and secured a strategic investment of $3.15 million – including $3 million from the anchor investor Homart Pharmaceuticals to provide Wellnex with manufacturing and product expertise as well as an export network and contacts.
The company says the funds will be used to advance the joint venture with OneLife Botanicals with the aim of being one of the first companies to bring an over-the-counter medicinal cannabis product to the Australian market.
“The total funds raised of $5.965 million will see us progress towards our goal of being one of the first companies to bring an over-the-counter medicinal cannabis product to the Australian market,” said CEO George Karafotias.
The funds will also be used to finance the inventory needed to launch new brands and product launches.
MICROBA (ASX:MAP)
In 2020, Microba entered into agreements with Europe’s largest pathology company SYNLAB (ETR:SYAB) to pursue a phased distribution strategy for Microba’s microbiome testing technology across Europe – and they now have extended this agreement until December 2028.
The agreement also provides a new framework for SYNLAB affiliate countries to rapidly expand distribution across Europe and Latin America.
OPYL (ASX:OPL)
Opyl’s clinical trial prediction and protocol design software has provided a world first in mapping and linking global clinical trial results data.
The AI-powered software accurately traced a random subset of clinical trials reported to global registries to their results, with 92% accuracy.
The company says this matters because only about 13% of the approximately 431,000 clinical trials registered on the US government’s website, ClinicalTrials.gov, have published their results on the site and no trials are linked over time to the as they progress between clinical phases.
The huge lack of information is a major problem for the medical research sector because no one benefits from past learnings and often repeats protocol design (trial plan) mistakes made in previous trials – which contributes to high failure rates and unnecessary waste of time and money on doomed research.
“TrialKey’s scalable Software-as-a-Service (SaaS) solution overcomes this problem by using machine learning/AI and natural language processing (NLP) to connect trials across multiple databases and global sources, reducing thereby reducing failure bias and thereby improving prediction and protocol design accuracy and software value,” the company states.
PROTEOMICS INTERNATIONAL (ASX:PIQ)
Proteomics has secured a $2 million funding boost through the expansion of the WA Proteomics Facility to accelerate the development of precision diagnostic tests in partnership with the University of Western Australia (UWA) and Bioplatforms Australia.
“There are clinical samples in biobanks and sample repositories across Australia that can be used to help fight chronic disease,” said Dr Richard Lipscombe.
“Similarly, analysis of seeds in national and international seed shops could help make breeding decisions that boost global agricultural production.
“All these biological samples are a precious and limited resource.
“By analyzing them faster and on a larger scale, we can accelerate the development of new precision diagnostic tests that could improve patient care or transform agricultural production.”
The expanded facility is expected to be fully operational in 2023.
WNX, MAP, OPL and PIQ stock prices today:
To Stockhead we tell it like it is. Although Wellnex Life and Opyl are Stockhead advertisers, they did not sponsor this article.
- Fitbit has launched a new Device Connect service to give doctors your data
- Wellnex Life has raised $2.8 million to achieve its goal of offering OTC medical cannabis in Australia
- Microba extends agreements with Europe’s largest pathology company through December 2028
Most of Fitbit’s revenue has historically come from the sale of its wearable devices, but its new Device Connect service targets healthcare professionals, doctors and hospitals looking for “accelerated analysis and information” in patients and clients.
Basically, healthcare providers would be able to monitor data and provide care outside of the doctor’s office, such as monitoring a patient’s condition before and after surgery, chronic disease management, or as part of a clinical research study.
Device Connect is already operational at Haga University Hospital in The Hague, the Netherlands, where researchers are using the data to help conduct a study for the early identification and prevention of vascular disease.
And because Google owns Fitbit, the plan is to use Google Cloud technology with pre-built dashboards, including a patient registration and consent app that lets healthcare professionals and businesses access to Fitbit data.
But don’t worry, apparently you’ll still be able to control what data you share and how it’s used.
You trust Google, right?
Who published health news today?
WELLNEX LIFE (ASX:WNX)
The company raised $2.815 million at $0.075 through a stock purchase plan (SPP) and secured a strategic investment of $3.15 million – including $3 million from the anchor investor Homart Pharmaceuticals to provide Wellnex with manufacturing and product expertise as well as an export network and contacts.
The company says the funds will be used to advance the joint venture with OneLife Botanicals with the aim of being one of the first companies to bring an over-the-counter medicinal cannabis product to the Australian market.
“The total funds raised of $5.965 million will see us progress towards our goal of being one of the first companies to bring an over-the-counter medicinal cannabis product to the Australian market,” said CEO George Karafotias.
The funds will also be used to finance the inventory needed to launch new brands and product launches.
MICROBA (ASX:MAP)
In 2020, Microba entered into agreements with Europe’s largest pathology company SYNLAB (ETR:SYAB) to pursue a phased distribution strategy for Microba’s microbiome testing technology across Europe – and they now have extended this agreement until December 2028.
The agreement also provides a new framework for SYNLAB affiliate countries to rapidly expand distribution across Europe and Latin America.
OPYL (ASX:OPL)
Opyl’s clinical trial prediction and protocol design software has provided a world first in mapping and linking global clinical trial results data.
The AI-powered software accurately traced a random subset of clinical trials reported to global registries to their results, with 92% accuracy.
The company says this matters because only about 13% of the approximately 431,000 clinical trials registered on the US government’s website, ClinicalTrials.gov, have published their results on the site and no trials are linked over time to the as they progress between clinical phases.
The huge lack of information is a major problem for the medical research sector because no one benefits from past learnings and often repeats protocol design (trial plan) mistakes made in previous trials – which contributes to high failure rates and unnecessary waste of time and money on doomed research.
“TrialKey’s scalable Software-as-a-Service (SaaS) solution overcomes this problem by using machine learning/AI and natural language processing (NLP) to connect trials across multiple databases and global sources, reducing thereby reducing failure bias and thereby improving prediction and protocol design accuracy and software value,” the company states.
PROTEOMICS INTERNATIONAL (ASX:PIQ)
Proteomics has secured a $2 million funding boost through the expansion of the WA Proteomics Facility to accelerate the development of precision diagnostic tests in partnership with the University of Western Australia (UWA) and Bioplatforms Australia.
“There are clinical samples in biobanks and sample repositories across Australia that can be used to help fight chronic disease,” said Dr Richard Lipscombe.
“Similarly, analysis of seeds in national and international seed shops could help make breeding decisions that boost global agricultural production.
“All these biological samples are a precious and limited resource.
“By analyzing them faster and on a larger scale, we can accelerate the development of new precision diagnostic tests that could improve patient care or transform agricultural production.”
The expanded facility is expected to be fully operational in 2023.
WNX, MAP, OPL and PIQ stock prices today:
To Stockhead we tell it like it is. Although Wellnex Life and Opyl are Stockhead advertisers, they did not sponsor this article.